The Ro/SS-A antigen was purified from an Epstein-Barr virustransformed human B lymphoblastoid cell line. The amino terminal amino acid sequence of the 60-kD polypeptide bearing this antigenic epitope was determined to be: 5 10 glu/ala-pro-ala-val-tyr-phe-lys-glu-gln-phe-leu-asp-gly-asp-15 20 gly-trp-thr-ser-arg-trp-ile-glu-ser-lys.
Introduction
An immune response to the Ro/SS-A antigen was originally described in patients with systemic lupus erythematosus (SLE) (1) and Sjogren's syndrome (SS) (2, 3) . Subsequently, antiRo/SS-A autoantibodies were implicated in the renal disease associated with SLE (4) and with extraglandular disease such as vasculitis in Sjogren's syndrome (5) . Recently, these autoantibodies have been found in a high percentage of patients with subacute cutaneous lupus erythematosus (SCLE) (6, 7) , as well Receivedfor publication I July 1987 and in revisedform 7 December 1987. as in neonatal lupus erythematosus (NLE)'/congenital heart block (8) (9) (10) (11) (12) (13) . Because of the association of maternal anti-Ro/ SS-A with the expression of NLE skin disease and the similarities between NLE and SCLE skin lesions, anti-Ro/SS-A antibodies have been implicated in the pathogenesis of these two disorders. Indeed, Ro/SS-A antigen has been detected in various types of human tissues, including skin and heart (14, 15) .
Recent studies have begun to elucidate the molecular structure of the Ro/SS-A antigen. Ro/SS-A is present on a particle comprised of RNA and a single polypeptide. In humans, four low molecular weight RNAs, HY 1, HY3, HY4, and HY5, have been found, while in the mouse only two (MY1 and MY2) have been detected (16, 17) . The protein moiety of the Ro/SS-A complex is a 60,000-mol-wt polypeptide that bears the Ro/SS-A antigenic epitope(s) (17) (18) (19) . Because of the wide implications of the Ro/SS-A antigen-antibody system in various human disease states, detailed information of the structure of this antigen is desirable. With pure Ro/SS-A in hand, one could study its interaction with autoantibodies, which would hopefully lead to a better understanding of the mechanism of autoimmune-related tissue injury.
The present investigation was initiated to further characterize the polypeptide component of the human Ro/SS-A antigen. Our studies have included the biochemical purification of the Ro/SS-A antigen, determination of the amino terminal amino acid sequence of the Ro/SS-A polypeptide, and an examination of the antigenic activity of synthetic peptides (SP) corresponding to a portion of the amino terminal sequence.
Methods
Antigen source. The Ro/SS-A antigen was isolated from an extract of an Epstein-Barr virus transformed human B lymphoblastoid cell line (Wil-2). The cells were grown in Eagle's medium supplemented with 2 mM glutamine, sodium pyruvate, nonessential amino acids, 10% fetal calf serum, penicillin (10,000 U/ml), and streptomycin (10 mg/ml).
The cells were centrifuged at 35 g for 12 min and washed with PBS (0.14 M NaCl, 0.01 M phosphate, pH 7.4) three times. The packed cells were mixed with the same volume of PBS containing 1 mM PMSF. The suspension was sonicated on ice with ten 15-s pulses using a heat system sonicator at a setting of 9. The sonicate was then centrifuged at 12,100 g for 1 h and the supernatant subjected to ammonium sulfate precipitation as previously described ( 18 Polybuffer ion exchange column chromatography. Polybuffer exchange (PBE) (PBE 94; Pharmacia Fine Chemicals, St. Louis, MO) was equilibrated with 24 mM borate buffer, pH 7.6, and packed into a 1.5 X 30-cm column. Ro/SS-A antigenic activity was eluted from the column by a previously described procedure (18) .
SDS-PAGE and Western blots. SDS-PAGE was performed according to the method of Laemmli (20). The proteins were separated using 12.5% polyacrylamide gel in the presence of SDS. Western blot analyses were performed as described by Towbin et al. (21) . Ro/SS-A obtained by native PAGE (N-PAGE) was electrophoresed in 12.5% SDS-PAGE. The resolved protein bands were transferred electrophoretically from the gel to a nitrocellulose sheet in buffer consisting of 192 mM glycine, 25 mM Tris, and 20% methanol vol/vol, pH 8.3, at 60 V, 200 ma for 4 h at room temperature followed by 100 mA for 16 h at 4°C. To ensure that the protein was properly transferred, one of the sheets was stained with 0.025% amido black in 20% ethanol/5% acetic acid and compared with the original gel-staining pattern. The remaining binding sites on the nitrocellulose sheet were blocked with 1% BSA in 10 mM Tris-HCI saline, pH 7.4, containing 0.05% Tween. The blots were then incubated with sera diluted with 1% BSA in 10 mM Tris buffer for 15 h. After washing three times with Tris buffer, "2'I-labeled goat anti-human IgG or horseradish peroxidase-conjugated goat anti-human IgG (Tago Inc., Burlingame, CA) was added. The blots were rinsed three times with Tris buffer followed by a distilled water wash. After air drying, the blots were exposed to XRP film for 3-4 d at -20°C. In experiments with horseradish peroxidase goat anti-human IgG, diaminobenzidine tetrahydrochloride (12.5 mg/100 ml Tris buffer, pH 7.6) was used.
ELISA. The native Ro/SS-A antigen (5 ug/ml) or SP (10 yg/ml) in PBS was added to wells ofa microtiter plate and incubated 16 h at 4°C. The plates were washed with PBS-Tween and the remaining sites were coated with 1% BSA for I h. After washing three times with PBSTween, sera diluted with 1% BSA, 0.5% bovine gamma globulin in PBS-Tween were added and incubated for 2 h. The plates were then washed three times with PBS-Tween. Peroxidase-conjugated goat anti-human IgG diluted 1:3,000 in PBS-Tween containing 1% BSA and 0.5% bovine gamma globulin was added and incubated for 2 h at room temperature. The plates were washed in a similar manner. The color was developed by adding a peroxidase substrate solution containing I mg/ml of 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid) (ABTS) and 0.005% H202 in 0.1 M McIvaine's buffer, pH 4.6.
The optical density was measured by a Titertek Multiskan Reader.
To determine the proportion of the total native Ro/SS-A antigenic activity that is present on the amino terminal SP, increasing amounts of keyhole limpet hemocyanin (KLH)-coupled SP (SP7-24) were preincubated with a monospecific patient anti-Ro/SS-A serum. After a 16-h incubation at 4°C, the inhibited serum aliquots were diluted to the appropriate concentrations and added to a native Ro/SS-A antigencoated plate. The degree of inhibition was then calculated by comparison with the reactivity of untreated anti-Ro/SS-A serum.
Protein sequencing. The purified Ro/SS-A antigen preparations, either from N-PAGE or from SDS-PAGE, were subjected to automated Edman degradation using either the gas-phase sequencer (model 470; Applied Biosystems, Inc., Foster City, CA) with the on line HPLC PTH 
Results
Purification of the Ro/SS-A molecule. Previous studies had established that the Ro/SS-A antigen was present in the 33-80% saturated ammonium sulfate fractions of lysates from the B lymphoblastoid cell line. These fractions were pooled and dialyzed against 24 mM borate buffer, pH 7.6, and applied to a polybuffer ion exchange column. After washing the column with 24 mM borate buffer (eluate with OD280 < 0.1), a stepwise sodium chloride gradient was applied to the column. The majority of La/SS-B antigen was eluted in the 0.1 and 0.2 M sodium chloride fraction, whereas all the Ro/SS-A antigen was recovered in the 0.5 and I M sodium chloride fractions ( The antigenically active material from the PBE column (0.5 and 1 M NaCl fraction) was further purified by electrophoresis in a 5.6% N-PAGE. After electrophoresis, the gel was divided into a series of 10-mm slices and the material was eluted from the gel with distilled water. By CIE, maximal Ro/SS-A antigen activity was located in the fraction with a retardation factor (Rf) of 9.0 (Fig. 2) , whereas the maximal La/SS-B activity was recovered in the region with an Rf of 0.7. When the antigenically active fraction from the N-PAGE was subjected to SDS-PAGE, it contained a single-stained band of 60,000 mol wt whose identity was confirmed by Western blot analysis (Fig. 3) .
Absorption spectrum of purified Ro/SS-A antigen. It has previously been demonstrated that the Ro/SS-A antigen is a complex of low molecular weight RNAs and a 60-kD polypeptide. Enzymatic digestion and immunoblot analysis has also indicated that the protein moiety is essential for the immunologic activity. Since in our purification scheme we used human autoantibodies to trace the Ro/SS-A antigenic activity, it was --68,000 ---. of interest to determine whether the purified material still contained low molecular weight RNA. Ultraviolet absorbance analysis performed on highly purified Ro/SS-A exhibited maximal absorption at 270 nm (Fig. 4) , indicating that this preparation still contained some RNA. Aminoterminal amino acid sequence of human Ro/SS-A antigen. Two Ro/SS-A antigenic preparations were sequenced: (i) the CIE-positive fraction from N-PAGE, and (ih) the 60-kD, immunoblot-active protein eluted from SDS-PAGE. 40 ug of the protein was analyzed each time and the following sequence was obtained: 5 10 glu/ala-pro-ala-val-tyr-phe-lys-glu-gln-phe-leu-asp-gly-asp- 15 20
gly-trp-thr-ser-arg-trp-ile-glu-ser-lys.
Two amino acids, glutamic acid and alanine, were found at the amino terminus of the molecule. This finding implies that multiple forms of this molecule might exist, an idea which has been suggested by others (22) . The amino terminal sequence of Ro/SS-A appears to be unique among 4,000 proteins so far searched by computer analysis. However, it does have limited sequence similarity to the human C4a (25%) (amino acids 511-538) (23), lipoprotein signal peptidase (33%) (amino acids 51-73) (24, 25) , epidermal growth factor-binding protein type B precursor (29%) (amino acids 39-58) (26) , human low density lipoprotein receptor precursor (17%) (amino acids 10-27) (27) , and B-2 glycoprotein (21%) (amino acids 264-282) (28) .
Antigenic activity ofRo/SS-A amino terminal SP (residues 6-19) (SP&19). A computer analysis of the amino terminal sequence of Ro/SS-A antigen using the method of Hopp and Woods (29) 
Discussion
This study provides the first information pertaining to the primary structure of the human Ro/SS-A antigen. We devised a purification scheme that allowed the isolation of this molecule from an Epstein-Barr virus transformed human B lymphoblastoid cell line. Enough material was isolated to obtain a partial amino terminal amino acid sequence, which revealed no striking homology to known proteins. We utilized the sequence data to synthesize two peptides, which allowed us to confirm that we had isolated authentic Ro/SS-A, since rabbit anti-peptide [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] antibodies reacted with native human Ro/SS-A antigen and monospecific anti-Ro/SS-A patient sera reacted with both SP. The chemical purification and partial primary structure of this autoantigen should provide an important link between a well-known, clinically relevant autoantibody and its antigen. In contrast to other abundant autoantigens such as Sm, RNP, histone, and La/SS-B, Ro/SS-A is present in only small amounts in normal tissue. In addition, the antigenic activity is known to be labile. We therefore developed a purification scheme that did not expose the antigen to chaotropic agents in order to minimize losses of antigenic activity. The combination of polybuffer ion exchange and N-PAGE allowed us to obtain highly purified Ro/SS-A with immunological specificity identical to that of the starting material. The purified Ro/SS-A molecule has a molecular weight of 60,000 which is consistent with the results obtained by several investigators (17) (18) (19) .
Serum from rabbits immunized by KLH-SP619 showed antibody activity toward native human Ro/SS-A antigen, confirming that the 6-19 peptide possesses the combination of 
